Brownsville CBD Shop Loses $10,000 in Inventory Due to New Hemp Rules
The Brownsville CBD shop inventory loss highlights challenges under new state hemp rules. This development affects cannabis retail compliance and inventory management. Clinicians and retailers should monitor these regulatory impacts closely.
New Research Highlights Cannabinoids and Fatty Liver Disease
Emerging cannabinoids fatty liver clinical relevance is gaining attention in recent studies. CBD and CBG show promise in improving fatty liver disease outcomes. Clinicians should monitor this evolving evidence carefully.
Smokable Hemp Can Be Sold in Texas Again … For Now
Texas smokable hemp legal status is currently in flux following recent court rulings. This uncertainty impacts patients and providers navigating hemp product use. Understanding these changes is crucial for clinical guidance and compliance.
Judge Blocks New State Rules That Ban Sale of Smokable Hemp
A Texas judge blocks smokable hemp ban, maintaining patient access to these products despite new state rules. This ruling highlights ongoing legal challenges and regulatory uncertainty. Patients and clinicians should stay informed about the implications…
Medicare Advances Coverage Policy for Hemp CBD Products
Medicare hemp cbd coverage policy is evolving to include certain hemp-derived products, marking a significant federal acceptance milestone. This policy shift may reduce cost barriers for seniors seeking cannabinoid therapeutics. Clinicians and patients…
Clinical Trial: CBD Assists in Recovery From Muscle-Related Injuries – NORML
A recent cbd muscle recovery clinical trial explores CBD's role in healing muscle-related injuries. The study highlights CBD's anti-inflammatory properties and potential for pain management. While promising, further clinical evidence is needed to confirm…
CED Digest: 35 Items — April 09, 2026
Alabama medical cannabis sales are gearing up for a spring 2026 launch, impacting clinical recommendations. Cannabis compounds CBD and CBG show promise for fatty liver disease treatment. Regulatory enforcement challenges in cannabis beverages also affect…
FloraWorks Announces TruCBN(TM) Readiness for CMS Substance Access Program
The CBN cannabinoid safety profile is advancing with FloraWorks' TruCBN readiness for CMS Substance Access. Clinical trial data show adverse events comparable to placebo, supporting safety. This progress may improve patient access to regulated…
Clinical Insights on the Cannabis Wellness Expo 2026
The cannabis wellness expo 2026 offers a unique blend of licensed products and wellness claims that clinicians should evaluate carefully. Patients attending the expo may have questions about new products and delivery methods. Clinicians must guide…
EU Continues Scrutiny on CBD Novel Food Applications
CBD regulatory uncertainty in the EU continues as six more novel food applications are rejected. This impacts patient access to standardized CBD products and complicates clinical recommendations. Understanding these regulatory challenges is essential for…